CARA THERAPEUTICS INC's ticker is CARA and the CUSIP is 140755109. A total of 177 filers reported holding CARA THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.17 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $248,810 | -40.6% | 148,101 | -0.0% | 0.00% | – |
| Q2 2023 | $419,168 | -65.0% | 148,116 | -39.3% | 0.00% | – |
| Q1 2023 | $1,198,929 | -55.8% | 244,181 | -3.4% | 0.00% | -100.0% |
| Q4 2022 | $2,715,000 | +55.4% | 252,672 | +35.3% | 0.00% | 0.0% |
| Q3 2022 | $1,747,000 | +6.3% | 186,693 | +3.7% | 0.00% | 0.0% |
| Q2 2022 | $1,644,000 | -25.2% | 180,018 | -0.5% | 0.00% | 0.0% |
| Q1 2022 | $2,199,000 | -5.9% | 180,973 | -5.6% | 0.00% | 0.0% |
| Q4 2021 | $2,336,000 | -16.4% | 191,795 | +6.1% | 0.00% | 0.0% |
| Q3 2021 | $2,794,000 | +1.8% | 180,824 | -6.0% | 0.00% | 0.0% |
| Q2 2021 | $2,745,000 | +34.7% | 192,398 | +126.0% | 0.00% | 0.0% |
| Q3 2018 | $2,038,000 | +64.9% | 85,128 | +6.0% | 0.00% | 0.0% |
| Q2 2017 | $1,236,000 | -17.0% | 80,322 | -0.8% | 0.00% | 0.0% |
| Q1 2017 | $1,490,000 | +53.8% | 80,982 | -22.4% | 0.00% | 0.0% |
| Q4 2016 | $969,000 | +132.4% | 104,343 | +258.0% | 0.00% | – |
| Q3 2015 | $417,000 | – | 29,148 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 2,799,058 | $42,350,000 | 22.29% |
| Chescapmanager LLC | 1,314,603 | $19,890,000 | 2.42% |
| Prosight Management, LP | 294,041 | $4,449,000 | 2.06% |
| DAFNA Capital Management LLC | 261,442 | $3,956,000 | 1.18% |
| Cypress Capital Management LLC (WY) | 81,269 | $1,230,000 | 1.06% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 626,583 | $9,480,000 | 1.02% |
| Carmignac Gestion | 1,851,443 | $28,012,000 | 0.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,465,000 | $37,295,000 | 0.22% |
| Ikarian Capital, LLC | 301,700 | $4,565,000 | 0.20% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 689,899 | $10,438,000 | 0.20% |